Stem cells for treatment of liver fibrosis/cirrhosis: clinical progress and therapeutic potential-Reference-Cited by-同舟云学术

Stem cells for treatment of liver fibrosis/cirrhosis: clinical progress and therapeutic potential

Published:2022-07-26 Issue:1 Volume:13 Page:
ISSN:1757-6512
Container-title:Stem Cell Research & Therapy
language:en
Short-container-title:Stem Cell Res Ther

Author:

Liu Pinyan,Mao Yongcui,Xie Ye,Wei Jiayun,Yao Jia^ORCID

Abstract

AbstractCost-effective treatment strategies for liver fibrosis or cirrhosis are limited. Many clinical trials of stem cells for liver disease shown that stem cells might be a potential therapeutic approach. This review will summarize the published clinical trials of stem cells for the treatment of liver fibrosis/cirrhosis and provide the latest overview of various cell sources, cell doses, and delivery methods. We also describe the limitations and strengths of various stem cells in clinical applications. Furthermore, to clarify how stem cells play a therapeutic role in liver fibrosis, we discuss the molecular mechanisms of stem cells for treatment of liver fibrosis, including liver regeneration, immunoregulation, resistance to injury, myofibroblast repression, and extracellular matrix degradation. We provide a perspective for the prospects of future clinical implementation of stem cells.

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Biochemistry, Genetics and Molecular Biology (miscellaneous),Molecular Medicine,Medicine (miscellaneous)

Link

https://link.springer.com/content/pdf/10.1186/s13287-022-03041-5.pdf

Reference147 articles.

1. Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70:151–71. https://doi.org/10.1016/j.jhep.2018.09.014.

2. Sepanlou SG, Safiri S, Bisignano C, Ikuta KS, Merat S, Saberifiroozi M, et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5:245–66. https://doi.org/10.1016/S2468-1253(19)30349-8.

3. Messina A, Luce E, Hussein M, Dubart-Kupperschmitt A. Pluripotent-stem-cell-derived hepatic cells: hepatocytes and organoids for liver therapy and regeneration. Cells. 2020. https://doi.org/10.3390/cells9020420.

4. Puppi J, Strom SC, Hughes RD, Bansal S, Castell JV, Dagher I, et al. Improving the techniques for human hepatocyte transplantation: report from a consensus meeting in London. Cell Transplant. 2012;21:1–10. https://doi.org/10.3727/096368911X566208.

5. Forbes SJ, Gupta S, Dhawan A. Cell therapy for liver disease: From liver transplantation to cell factory. J Hepatol. 2015;62:S157–69. https://doi.org/10.1016/j.jhep.2015.02.040.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mi-BMSCs alleviate inflammation and fibrosis in CCl4-and TAA-induced liver cirrhosis by inhibiting TGF-β/Smad signaling;Materials Today Bio;2024-04

2. Chronic Liver Diseases: What is Up?;Journal of Clinical Medicine;2024-01-22

3. Therapeutic potential of stem cells in regeneration of liver in chronic liver diseases: Current perspectives and future challenges;Pharmacology & Therapeutics;2024-01

4. Old age as a risk factor for liver diseases: Modern therapeutic approaches;Experimental Gerontology;2023-12

5. The role of ischaemia-reperfusion injury and liver regeneration in hepatic tumour recurrence;JHEP Reports;2023-11